Drug Profile
Bimosiamose
Alternative Names: BIMO; Bimosiamose disodium; TBC 1269; TBC 1269zLatest Information Update: 20 Aug 2015
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Developer Revotar Biopharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Glycoconjugates; Hexanes; Skin disorder therapies; Small molecules
- Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute lung injury; Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Plaque psoriasis
Most Recent Events
- 28 Sep 2011 Final efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011)
- 30 Mar 2011 Discontinued - Phase-I for Adult respiratory distress syndrome in Germany (Inhalation)
- 30 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Germany (Intradermal)